Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, Asia, South America, Africa, and Australia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, the company offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.

Currency in USD	2025
Operating Income	534.93 Million
Income Before Tax	542.38 Million
Income Tax Expense	91.25 Million
Net Income	451.12 Million
Eps	15.64
Epsdiluted	15.28
Weighted Average Shs Out	28.85 Million
Weighted Average Shs Out Dil	29.53 Million
Research And Development Expenses	N/A
Selling General And Administrative Expenses	197.56 Million
Depreciation And Amortization	28.12 Million
Interest Expense	N/A
Interest Income	N/A
Net Interest Income	12.78 Million
Premiums Earned	N/A
Policyholder Benefits	N/A
Gross Profit	760.62 Million
Ebitda	563.06 Million
Source	edgar
Ebit	534.93 Million

Medpace Holdings, Inc. Annual Reports (10-K)